Literature DB >> 21524897

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Laurent Verkoczy1, Garnett Kelsoe, M Anthony Moody, Barton F Haynes.   

Abstract

Although antibodies can be elicited by HIV-1 infection or immunization, those that are broadly neutralizing (bnAbs) are undetectable in most individuals, and when they do arise in HIV-1 infection, only do so years after transmission. Until recently, the reasons for difficulty in inducing such bnAbs have been obscure. Recent technological advances in isolating bnAbs from rare patients have increased our knowledge of their specificities and features, and along with gene-targeting studies, have also begun uncovering evidence of immunoregulatory roadblocks preventing their induction. One crucial avenue towards developing an effective HIV-1 vaccine is to harness this emerging information into the rational design of immunogens and formulation of adjuvants, such that structural and immunological hurdles to routinely eliciting bnAbs can be overcome.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21524897      PMCID: PMC3139952          DOI: 10.1016/j.coi.2011.04.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  68 in total

Review 1.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Authors:  Barton F Haynes; M Anthony Moody; Laurent Verkoczy; Garnett Kelsoe; S Munir Alam
Journal:  Hum Antibodies       Date:  2005

Review 2.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

3.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

4.  Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques.

Authors:  Flavia Ferrantelli; Kathleen A Buckley; Robert A Rasmussen; Alistair Chalmers; Tao Wang; Pei-Lin Li; Alison L Williams; Regina Hofmann-Lehmann; David C Montefiori; Lisa A Cavacini; Hermann Katinger; Gabriela Stiegler; Daniel C Anderson; Harold M McClure; Ruth M Ruprecht
Journal:  Virology       Date:  2006-09-25       Impact factor: 3.616

5.  Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

Authors:  Barton F Haynes; Judith Fleming; E William St Clair; Herman Katinger; Gabriela Stiegler; Renate Kunert; James Robinson; Richard M Scearce; Kelly Plonk; Herman F Staats; Thomas L Ortel; Hua-Xin Liao; S Munir Alam
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

6.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.

Authors:  Alexandra Trkola; Herbert Kuster; Peter Rusert; Beda Joos; Marek Fischer; Christine Leemann; Amapola Manrique; Michael Huber; Manuela Rehr; Annette Oxenius; Rainer Weber; Gabriela Stiegler; Brigitta Vcelar; Hermann Katinger; Leonardo Aceto; Huldrych F Günthard
Journal:  Nat Med       Date:  2005-05-08       Impact factor: 53.440

Review 7.  B-1 B cell development.

Authors:  Richard R Hardy
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

8.  Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors.

Authors:  Ivaylo I Ivanov; Robert L Schelonka; Yingxin Zhuang; G Larry Gartland; Michael Zemlin; Harry W Schroeder
Journal:  J Immunol       Date:  2005-06-15       Impact factor: 5.422

Review 9.  Sites and stages of autoreactive B cell activation and regulation.

Authors:  Mark J Shlomchik
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

10.  HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane.

Authors:  Zhen-Yu J Sun; Kyoung Joon Oh; Mikyung Kim; Jessica Yu; Vladimir Brusic; Likai Song; Zhisong Qiao; Jia-huai Wang; Gerhard Wagner; Ellis L Reinherz
Journal:  Immunity       Date:  2008-01       Impact factor: 31.745

View more
  67 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.

Authors:  Mattia Bonsignori; Kevin Wiehe; Sebastian K Grimm; Rebecca Lynch; Guang Yang; Daniel M Kozink; Florence Perrin; Abby J Cooper; Kwan-Ki Hwang; Xi Chen; Mengfei Liu; Krisha McKee; Robert J Parks; Joshua Eudailey; Minyue Wang; Megan Clowse; Lisa G Criscione-Schreiber; M Anthony Moody; Margaret E Ackerman; Scott D Boyd; Feng Gao; Garnett Kelsoe; Laurent Verkoczy; Georgia D Tomaras; Hua-Xin Liao; Thomas B Kepler; David C Montefiori; John R Mascola; Barton F Haynes
Journal:  J Clin Invest       Date:  2014-03-10       Impact factor: 14.808

Review 3.  Host controls of HIV broadly neutralizing antibody development.

Authors:  Garnett Kelsoe; Barton F Haynes
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

4.  Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies.

Authors:  Jinsong Zhang; S Munir Alam; Hilary Bouton-Verville; Yao Chen; Amanda Newman; Shelley Stewart; Frederick H Jaeger; David C Montefiori; S Moses Dennison; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2014-01-24       Impact factor: 5.422

5.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

Review 6.  Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates.

Authors:  Joern E Schmitz; Birgit Korioth-Schmitz
Journal:  Curr Opin HIV AIDS       Date:  2013-07       Impact factor: 4.283

7.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

8.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

Review 9.  Role of IL-21 and IL-21 receptor on B cells in HIV infection.

Authors:  Suresh Pallikkuth; Anita Parmigiani; Savita Pahwa
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

Review 10.  HIV-1 neutralizing antibodies: understanding nature's pathways.

Authors:  John R Mascola; Barton F Haynes
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.